YOLFTbeta
HLB Pharmaceutical Co. Ltd

HLB Pharmaceutical Co. Ltd

047920 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

7,110.00KRW-190.00 (-2.60%)

Price History

Full chart

Market Stats

Previous Close7,300.00
Open7,380.00
Day Range7,100.00 – 7,540.00
52-Week Range5,529.15 – 20,503.93
Volume367.17K
Market Cap358.05B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.24
50-Day Avg8,005.80
200-Day Avg13,209.75

About

HLB Pharmaceutical Co., Ltd. researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxant, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Jae-Hyung Park
  • Employees197
  • Headquarters27, Gyeonggang-ro, Namyangju-si, South Korea, 12244, Korea
  • Websitehttps://www.hlbpharma.co.kr

Leadership

  • Mr. Jae-Hyung ParkCEO & Executive Director · b. 1966
  • Mr. Kyung-Won ParkDirector of Sales · b. 1978
  • Mr. Man-Gyu KimVP of Strategic Planning & Executive Director · b. 1975

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue17.16B17.71B20.35B15.56B20.54B36.10B40.57B62.85B107.48B135.95B137.08B205.58B
Growth (%)-+3.20%+14.87%-23.54%+32.03%+75.75%+12.39%+54.92%+71.01%+26.49%+0.83%+49.97%
Cost of Revenue12.47B13.82B14.86B12.75B16.08B18.06B18.22B27.50B43.47B52.97B50.50B99.08B
Gross Profit4.70B3.89B5.49B2.80B4.47B18.04B22.35B35.36B64.01B82.99B86.58B106.50B
Gross Margin27.38%21.96%26.98%18.02%21.74%49.98%55.09%56.25%59.55%61.04%63.16%51.81%
Operating Expense4.27B4.86B5.08B7.17B9.88B17.04B24.43B34.87B70.43B88.43B97.32B105.44B
Operating Income433.45M-965.65M405.55M-4.37B-5.41B1.00B-2.08B486.24M-6.42B-5.44B-10.74B1.06B
Operating Margin2.53%-5.45%1.99%-28.06%-26.34%2.78%-5.13%0.77%-5.97%-4.01%-7.84%0.52%
EBITDA---------1.39B-2.04B6.88B9.84B
EBITDA Margin---------1.30%-1.50%5.02%4.78%
Net Income304.58M-2.36B577.41M-5.45B-7.06B472.65M-74.84B-13.23B-11.78B-19.43B2.02B4.57B
Net Income Margin1.77%-13.35%2.84%-35.01%-34.37%1.31%-184.47%-21.04%-10.96%-14.29%1.47%2.22%
R&D1.39B1.16B2.23B2.74B2.47B-1.41B2.52B3.09B2.31B2.45B3.34B
R&D as % of Total Revenue8.13%6.56%10.94%17.58%12.05%-3.48%4.01%2.87%1.70%1.79%1.62%
Interest Expense00000012.66B15.88B5.02B11.77B621.14M738.08M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%31.19%25.26%4.67%8.66%0.45%0.36%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.43B24.85B41.24B39.85B36.42B46.39B111.42B127.63B142.18B141.35B157.93B170.68B
Total Liabilities16.62B12.67B22.34B23.04B19.42B29.04B66.80B49.25B56.25B53.20B41.53B45.53B
Total Equity4.81B12.18B18.90B16.80B17.00B17.36B44.62B78.38B85.93B88.15B116.40B125.15B
Cash1.82B5.48B2.92M5.35B3.03B2.74B3.17M2.50M317.00K4.77B10.49B7.61B
Total Debt-3.92B13.72B4.57B2.61B4.73B4.32B-----
Net Debt------23.07B23.47B14.03B16.99B4.51B7.39B

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow1.54B-769.59M-213.11M-784.30M-1.78B1.35B-403.36M-1.32B-2.76B-18.32B6.84B568.98M
Investing Cash Flow-3.75B-623.11M-15.35B1.17B309.09M-6.94B-56.11B-15.76B-13.28B9.58B-12.26B-
Financing Cash Flow3.78B5.06B13.91B1.15B-851.25M5.30B67.85B9.63B19.15B3.76B11.14B-
Capital Expenditure2.26B2.33B4.77B2.24B1.10B1.40B2.98B49.51B2.90B4.26B3.09B7.21B
Free Cash Flow-------3.38B-50.83B-5.66B-22.57B3.75B-6.64B
FCF to OCF------838.78%3847.05%204.98%123.23%54.81%-1167.27%

Earnings

Report DateDec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------------------------------
EPS Actual-187.99-13.36-10.1415.6752.53-148.886.12-28.17-166.167.74-158.50-74.01-178.50-47.3171.9061.25-54.397.9617.51-568.58-2910.54-136.81-226.78-247.2355.87-115.89-66.35-145.17-69.3521.66-565.67-236.76157.74-47.209.3827.4863.2745.4325.69-4.5162.8520.10-1.59
Surprise-------------------------------------------
Timing-------------------------------------------

Key Statistics & Ratios

Market Cap358.05B
Enterprise Value366.51B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.58
Price / Book2.47
Revenue (TTM)251.95B
Gross Profit (TTM)116.16B
EBITDA6.41B
Profit Margin1.09%
Operating Margin-0.05%
Return on Equity2.18%
Return on Assets0.69%
Shares Outstanding35.59M
Shares Float24.81M
Beta0.24
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 4, 2026446:411
  • Apr 12, 20163:2